[ad_1]
The National Academies of Sciences, Engineering, and Medicine hosted a public briefing in July on their 2022 report, Guidance on Per- and Polyfluoroalkyl Substances (PFAS) Exposure, Testing, and Clinical Follow-up. The report was sponsored by NIEHS and the Agency for Toxic Substances and Disease Registry (ATSDR), prompted by tensions between people in PFAS-exposed communities who want preventive care and clinicians who may not know what care to provide. The report recommends that the Centers for Disease Control and Prevention (CDC) advise clinicians to offer PFAS blood tests to people who likely have a history of elevated exposure and provides advice on further clinical care, such as regular screenings. The report details how to test, what to test for, and the risks and benefits of testing. It also recommends that the CDC and public health departments support clinicians by creating educational resources on PFAS exposure, potential health effects, and testing. The briefing covered topics from the report such as the approach to the study, the findings on the health effects of PFAS, recommendations to inform clinical care, and suggestions for revising ATSDR clinical guidance. The recording of the briefing and the meeting materials are now available.
[ad_2]
